Maxillent Ltd. provides innovative solutions that are revolutionizing the field of dental implants. The company’s flagship product, the iRaise sinus lift implant, transforms the sinus lift procedure from a technically demanding, traumatic surgical intervention into a simple, minimally invasive implantation procedure. iRaise dramatically improves patients’ quality of life and reduces the risk of post-procedure complications. Patients no longer need to suffer post-operative swelling, bruising and discomfort, and can return to their daily routine almost immediately. The iRaise procedure has been proven in highly successful clinical studies and has an excellent safety profile.
In addition to the iRaise sinus lift implant, Maxillent offers a comprehensive range of iSure™ dental implants, prosthetics, bone graft materials and surgical tools that cover the entire spectrum of dental implant procedures.
Maxillent’s development and manufacturing facilities are certified for ISO 13485. All the company’s products have CE Mark approval and are commercially available in Europe and Israel. FDA approval is currently in process. Maxillent’s uncompromising commitment to quality and strict adherence to regulatory guidelines ensures that it not only meets, but exceeds the industry’s most stringent quality standards.
Maxillent’s technology is based on proprietary R&D, with a rich intellectual property portfolio protected by US patents no. 7934929, 8029284, and several additional patents pending in the US and other countries.
The company's team of engineers, researchers and implantation specialists are among the world’s leading researchers in the field, and the company’s Scientific Advisory Board comprise key opinion leaders and researchers.